Semaglutide directly strengthened the contraction force of isolated human atrial heart tissue at therapeutic concentrations, working through the cAMP-protein kinase pathway and calcium release mechanisms.
Direct positive inotropy at therapeutic dosesSemaglutide increased the force of contraction in human atrial tissue at concentrations achievable during standard therapeutic dosing, suggesting a clinically relevant direct cardiac effect.
What the researchers found
Semaglutide produced a concentration- and time-dependent positive inotropic effect (increased contraction force) in isolated human right atrial preparations obtained during open-heart surgery. The effect was accompanied by increased rates of tension development and relaxation, plus reduced muscle relaxation time.
Mechanistically, the positive inotropic effect was attenuated by H89 (a cAMP-dependent protein kinase inhibitor) and by ryanodine (an inhibitor of sarcoplasmic calcium release), indicating the effect is mediated through the cAMP/PKA pathway and intracellular calcium handling. Notably, semaglutide up to 100 nM failed to produce a positive inotropic effect in mouse left atrial preparations, highlighting a species-specific response.
Why it matters
With millions of patients taking semaglutide for diabetes and obesity, understanding its direct cardiac effects is critical. GLP-1 receptor agonists have shown cardiovascular benefits in clinical trials, but whether they act directly on heart muscle or only indirectly through metabolic improvements has been unclear. This study provides the first evidence that semaglutide directly increases human heart contractility at therapeutic concentrations — a finding with important implications for patients with heart failure.
How the study worked
Ex vivo contraction experiments using isolated human right atrial muscle preparations obtained from patients undergoing open-heart surgery. Tissue strips were exposed to increasing concentrations of semaglutide while measuring force of contraction, rates of tension development and relaxation. Pharmacological inhibitors (H89, ryanodine) were used to probe the signaling mechanism. Mouse left atrial preparations were tested for comparison.
What this study cannot tell us
This was an ex vivo study on isolated tissue strips, which doesn't capture the complexity of an intact beating heart with neural and hormonal inputs. Tissue was from surgical patients who likely had preexisting cardiac conditions, which may not represent healthy hearts. The effect was not seen in mouse tissue, making preclinical animal modeling difficult. The functional significance of the observed inotropic effect in the context of whole-heart function and clinical outcomes is unknown. Only atrial tissue was tested — ventricular effects remain unstudied.
How to read the evidence
This is a mechanistic ex vivo study using human tissue — stronger than cell culture but not a clinical trial. The use of genuine human cardiac tissue from surgical patients and pharmacological mechanism probing provides solid mechanistic evidence, though clinical significance remains to be established.
When this study was published
Published in 2024, this is very recent and highly relevant given the ongoing expansion of semaglutide use and increasing focus on its cardiovascular effects. The finding adds mechanistic depth to the clinical trial data on GLP-1 cardiovascular benefits.
The bigger picture
The cardiovascular effects of GLP-1 receptor agonists are one of the hottest topics in cardiology. The SELECT and STEP-HFpEF trials showed semaglutide reduces cardiovascular events and improves heart failure symptoms, but the mechanisms have been attributed mainly to weight loss, reduced inflammation, and metabolic improvements. This study adds a potentially game-changing piece: direct positive inotropy in human heart tissue. If confirmed in vivo, it would mean semaglutide has a direct heart-strengthening effect beyond its metabolic benefits.
Questions still open
- Does semaglutide's direct positive inotropic effect on human heart tissue contribute to the cardiovascular benefits seen in clinical trials?
- Would this direct cardiac effect be beneficial or potentially harmful in patients with existing heart conditions like heart failure or atrial fibrillation?
- Why does semaglutide affect human but not mouse atrial tissue — are there species differences in cardiac GLP-1 receptor expression or signaling?
Common questions
Does semaglutide make the heart beat stronger?
Could this explain why GLP-1 drugs are good for the heart?
Read the original research
Contractile Effects of Semaglutide in the Human Atrium.
Pharmaceutics, 16(9)
Citation
Neumann, Joachim; Hadová, Katarína; Klimas, Jan; Hofmann, Britt; Gergs, Ulrich. (2024). Contractile Effects of Semaglutide in the Human Atrium.. Pharmaceutics, 16(9). https://doi.org/10.3390/pharmaceutics16091139